We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Urease Test Developed to Diagnose H. pylori Infection in Asymptomatic Patients

By LabMedica International staff writers
Posted on 25 Oct 2011
A new rapid urease assay offers high sensitivity and accuracy for diagnosis of Helicobacter pylori in untreated patients.

Dyspepsia is a multifaceted range of symptoms related to the upper gastrointestinal (GI) tract. More...
Population-based surveys have shown dyspepsia to be a global problem with 15% to 40% of the populace complaining of upper GI symptoms. Although several guidelines recommend an initial noninvasive “test and treat” approach for the diagnosis of H. pylori in primary care if patients do not complain of acute symptoms and are younger than 45-50 years, many dyspeptic patients are still referred for endoscopy.

In a recent cohort of US patients, about one-third of all upper endoscopic procedures were performed for patients with dyspeptic symptoms without alarm symptoms. In some countries, the high prevalence of gastric cancer in young dyspeptic patients also makes early endoscopy an important feature of dyspepsia management.

Endoscopic tests for H. pylori have progressed in the past 10 years and one area of growth has been the speed with which the rapid urease test (RUT) can be read. A new urease test, the Urea ultrafast-test--UFT 300, developed by ABS Advanced Biomedical Systems (Cernusco sul Naviglio, Italy) can be read in five minutes. The test, which was approved in the European Union, has the potential to simplify the clinical management further by allowing the result of the test to be included in the endoscopy report when patient leaves the endoscopy unit.

To assess the diagnostic accuracy of this new rapid urease test to diagnose H. pylori infection in untreated patients using an independent external reference standard, scientists from the department of internal medicine and gastroenterology at the University of Bologna (Italy) examined 1,000 consecutive dyspeptic patients and demonstrated that the new rapid urease UFT300 test offers high sensitivity (94.5%) and accuracy (100%), with a considerably shorter time period to read both a positive and a negative test.

The study was published January 2010 in the journal Alimentary Pharmacology & Therapeutics journal.

Related Links:
ABS Advanced Biomedical Systems
University of Bologna



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.